Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. T-LITEs incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected T-cell cytotoxic activity. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Mateo, California.
View Top Employees from Soteria BiotherapeuticsWebsite | https://www.soteriabiotherapeutics.com/ |
Employees | 14 (14 on RocketReach) |
Founded | 2018 |
Address | 1900 Alameda De Las Pulgas, San Mateo, California 94403, US |
Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
Industry | Biotechnology Research, Drug Discovery, Biotechnology |
Looking for a particular Soteria Biotherapeutics employee's phone or email?
14 people are employed at Soteria Biotherapeutics.
Soteria Biotherapeutics is based in San Mateo, California.